Approval · Notice of Compliance 3824 · 1997
MONOPRIL: Notice of Compliance 3824
Issued April 24, 1997
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3824
- Date
- April 24, 1997
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Provides for use in patients with symptomatic congestive heart failure
- Therapeutic class
- Angiotensin converting enzyme inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MONOPRIL | Not yet assigned | — |
Medicinal ingredients
- FOSINOPRIL SODIUM 5 MG per TAB
- FOSINOPRIL SODIUM 10 MG per TAB
- FOSINOPRIL SODIUM 20 MG per TAB